만성폐쇄성폐질환 치료제 시장(2026-2030년)

The global chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7943.3 mn during 2025-2030, accelerating at a CAGR of 6.2% during the forecast period. The report on the global chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of copd, strong pipeline and new drug approvals, growing demand for fixed-dose combinations.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global chronic obstructive pulmonary disease drugs market is segmented as below:

By Product

• Combination therapy
• Monotherapy

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Route Of Administration

• Inhalation
• Oral
• Injectable

By Disease Type

• Chronic bronchitis
• Emphysema

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • The Netherlands
  • Spain
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the expanding research in curative approaches as one of the prime reasons driving the global chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and rising expansion of inhalation therapies will lead to sizable demand in the market.

The report on the global chronic obstructive pulmonary disease drugs market covers the following areas:

• Global chronic obstructive pulmonary disease drugs market sizing
• Global chronic obstructive pulmonary disease drugs market forecast
• Global chronic obstructive pulmonary disease drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Boehringer Ingelheim GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Philip Morris International, SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Ltd., Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc.. Also, the global chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Disease Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Chronic Obstructive Pulmonary Disease Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Chronic Obstructive Pulmonary Disease Drugs Market 2020 - 2024 ($ million)
• 5.2 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.5 Disease Type segment analysis 2020 - 2024
  • Historic Market Size - Disease Type Segment 2020 - 2024 ($ million)
• 5.6 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.7 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 AI Impact on Global Chronic Obstructive Pulmonary Disease Drugs Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product

• 8.1 Market segments
• 8.2 Comparison by Product
• 8.3 Combination therapy - Market size and forecast 2025-2030
• 8.4 Monotherapy - Market size and forecast 2025-2030
• 8.5 Market opportunity by Product
  • Market opportunity by Product ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Hospital pharmacies - Market size and forecast 2025-2030
• 9.4 Retail pharmacies - Market size and forecast 2025-2030
• 9.5 Online pharmacies - Market size and forecast 2025-2030
• 9.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Route of Administration

• 10.1 Market segments
• 10.2 Comparison by Route of Administration
• 10.3 Inhalation - Market size and forecast 2025-2030
• 10.4 Oral - Market size and forecast 2025-2030
• 10.5 Injectable - Market size and forecast 2025-2030
• 10.6 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

11 Market Segmentation by Disease Type

• 11.1 Market segments
• 11.2 Comparison by Disease Type
• 11.3 Chronic bronchitis - Market size and forecast 2025-2030
• 11.4 Emphysema - Market size and forecast 2025-2030
• 11.5 Market opportunity by Disease Type
  • Market opportunity by Disease Type ($ million)

12 Customer Landscape

• 12.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

13 Geographic Landscape

• 13.1 Geographic segmentation
• 13.2 Geographic comparison
• 13.3 North America - Market size and forecast 2025-2030
  • 13.3.1 US - Market size and forecast 2025-2030
  • 13.3.2 Canada - Market size and forecast 2025-2030
  • 13.3.3 Mexico - Market size and forecast 2025-2030
• 13.4 Europe - Market size and forecast 2025-2030
  • 13.4.1 Germany - Market size and forecast 2025-2030
  • 13.4.2 UK - Market size and forecast 2025-2030
  • 13.4.3 France - Market size and forecast 2025-2030
  • 13.4.4 Italy - Market size and forecast 2025-2030
  • 13.4.5 Russia - Market size and forecast 2025-2030
  • 13.4.6 The Netherlands - Market size and forecast 2025-2030
  • 13.4.7 Spain - Market size and forecast 2025-2030
• 13.5 Asia - Market size and forecast 2025-2030
  • 13.5.1 China - Market size and forecast 2025-2030
  • 13.5.2 Japan - Market size and forecast 2025-2030
  • 13.5.3 India - Market size and forecast 2025-2030
  • 13.5.4 South Korea - Market size and forecast 2025-2030
  • 13.5.5 Indonesia - Market size and forecast 2025-2030
  • 13.5.6 Singapore - Market size and forecast 2025-2030
  • 13.5.7 Thailand - Market size and forecast 2025-2030
• 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 13.6.1 Australia - Market size and forecast 2025-2030
  • 13.6.2 UAE - Market size and forecast 2025-2030
  • 13.6.3 Brazil - Market size and forecast 2025-2030
  • 13.6.4 South Africa - Market size and forecast 2025-2030
  • 13.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 13.6.6 Turkey - Market size and forecast 2025-2030
• 13.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

14 Drivers, Challenges, and Opportunity

• 14.1 Market drivers
  • Rising prevalence of COPD
  • Strong pipeline and new drug approvals
  • Growing demand for fixed-dose combinations
• 14.2 Market challenges
  • Low diagnosis rates of diseases
  • High cost of conducting clinical trials
  • Obstacles to reimbursement
• 14.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 14.4 Market opportunities
  • Expanding research in curative approaches
  • Advances in drug delivery devices
  • Rising expansion of inhalation therapies

15 Competitive Landscape

• 15.1 Overview
• 15.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 15.3 Landscape disruption
  • Overview on factors of disruption
• 15.4 Industry risks
  • Impact of key risks on business

16 Competitive Analysis

• 16.1 Companies profiled
  • Companies covered
• 16.2 Company ranking index
  • Company ranking index
• 16.3 Market positioning of companies
  • Matrix on companies position and classification
• 16.4 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 16.5 Boehringer Ingelheim GmbH
  • Boehringer Ingelheim GmbH - Overview
  • Boehringer Ingelheim GmbH - Product / Service
  • Boehringer Ingelheim GmbH - Key news
  • Boehringer Ingelheim GmbH - Key offerings
  • SWOT
• 16.6 Cadila Pharmaceuticals Ltd.
  • Cadila Pharmaceuticals Ltd. - Overview
  • Cadila Pharmaceuticals Ltd. - Product / Service
  • Cadila Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 16.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 16.8 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 16.9 Glenmark Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product / Service
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 16.10 Innoviva Inc.
  • Innoviva Inc. - Overview
  • Innoviva Inc. - Product / Service
  • Innoviva Inc. - Key news
  • Innoviva Inc. - Key offerings
  • SWOT
• 16.11 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 16.12 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 16.13 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 16.14 SHIONOGI Co. Ltd.
  • SHIONOGI Co. Ltd. - Overview
  • SHIONOGI Co. Ltd. - Product / Service
  • SHIONOGI Co. Ltd. - Key offerings
  • SWOT
• 16.15 Sumitomo Pharma Co. Ltd.
  • Sumitomo Pharma Co. Ltd. - Overview
  • Sumitomo Pharma Co. Ltd. - Business segments
  • Sumitomo Pharma Co. Ltd. - Key offerings
  • Sumitomo Pharma Co. Ltd. - Segment focus
  • SWOT
• 16.16 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 16.17 Theravance Biopharma Inc.
  • Theravance Biopharma Inc. - Overview
  • Theravance Biopharma Inc. - Product / Service
  • Theravance Biopharma Inc. - Key offerings
  • SWOT
• 16.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

17 Appendix

• 17.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 17.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 17.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 17.4 Research methodology
  • Research methodology
• 17.5 Data procurement
  • Information sources
• 17.6 Data validation
  • Data validation
• 17.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 17.8 Data synthesis
  • Data synthesis
• 17.9 360 degree market analysis
  • 360 degree market analysis
• 17.10 List of abbreviations
  • List of abbreviations